June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Association between Antiplatelet or Anticoagulant Drugs and Retinal Hemorrhage in the Comparison of AMD Treatments Trials (CATT)
Author Affiliations & Notes
  • Gui-Shuang Ying
    Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Maureen G Maguire
    Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Ebenezer Daniel
    Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Juan E Grunwald
    Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Daniel F Martin
    Ophthalmology, Cleveland Clinic, Cleveland, OH
  • Footnotes
    Commercial Relationships Gui-Shuang Ying, Janssen R&D (C); Maureen Maguire, Genentech (C), IDx (F); Ebenezer Daniel, None; Juan Grunwald, None; Daniel Martin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gui-Shuang Ying, Maureen G Maguire, Ebenezer Daniel, Juan E Grunwald, Daniel F Martin, ; Association between Antiplatelet or Anticoagulant Drugs and Retinal Hemorrhage in the Comparison of AMD Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2569.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the association between use of antiplatelet (AP) or anticoagulant (AC) drugs and retinal hemorrhage in CATT participants with neovascular age-related macular degeneration (AMD).

 
Methods
 

1185 CATT participants with untreated active choroidal neovascularization (CNV) secondary to AMD were enrolled. At baseline, trained readers at the CATT Photograph Reading Center evaluated on baseline fundus photographs, the presence and size (≤1, 1 to ≤2, >2 DA) of retinal hemorrhage associated with the neovascular lesion. At enrollment, the participants were interviewed for current use of AP/AC drugs (aspirin, warfarin, clopidogrel, etc.) including the type, dose, frequency and start date. The associations between use of AP/AC drugs and retinal hemorrhage at baseline were evaluated using Fisher exact test and logistic regression with adjustment for age, gender, smoking status, diabetes, medical history of cardiovascular diseases, and bilaterality of CNV.

 
Results
 

Among 1165 CATT participants with gradable photographs, 724 (62.1%) had retinal hemorrhage at baseline, the majority (84%) of hemorrhages were ≤1 DA, 59 (8.1%) were 1 to 2 DA, and 54 (7.5%) were >2 DA. 608 (52.2%) participants used AP/AC at baseline (476 used aspirin, 98 used warfarin, 80 used clopidogrel), 514 (44.1%) used AP only, 77 (6.6%) used AC only, and 17 (1.5%) used both AP and AC. Participants with retinal hemorrhage at baseline were comparable to those without retinal hemorrhage except that they were older (80 vs. 78 years, p<0.0001) and had lower diastolic blood pressure (74.9 vs. 76.2 mmHg, p=0.03). Retinal hemorrhage was present in 64.5% of AP/AC users and in 59.6% of non-users (p=0.09), the adjusted odds ratio was 1.18 (95% CI: 0.91-1.51, p=0.21). There is no significant association between use of AP/AC and size of retinal hemorrhage (p=0.34). No association was identified between type, dose or duration of AP/AC use and presence of retinal hemorrhage (Table 1).

 
Conclusions
 

Among the CATT participants with active neovascular AMD, the use of antiplatelet and anticoagulant drugs was not significantly associated with retinal hemorrhage at baseline.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×